FORM 4

Check this box if no longer subject to Section 16.

Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB	APPROVAL
-----	-----------------

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

Instruction 1(b).

Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2025	X Director 10% Owner X Officer (give title below) Other (specify below)
(Street) SAN DIEGO CA 92123 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

		Table l	I - Non-Deriva	ative S	Securities Acqu	ired, D	isposed of, or l	Beneficially Owned		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			equired (A) or Securities Beneficially Owned Following Reported Direct(D) or Indirect (I) Ownership Form: 7. Nature of Indirect Beneficial Ownership		
			Code	V	Amount	(A) or (D)	Price	\		
ResMed Common Stock	12/08/2025		M (1)		4,991	A	\$146.34	471,214	D	
ResMed Common Stock	12/08/2025		S (1)		4,991	D	\$251.4117 (2)	466,223	D	
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

				Table				Acquired, Disponts, options, co			ed				
1. Title of Derivative Security (Instr.3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8		5. Numb Derivativ Securitie Acquired Disposed (Instr. 3,	ve s l (A) or l of (D)	6. Date Exerc Expiration Da (Month/Day/	ate	7. Title and Securities U Derivative S (Instr. 3 and	Inderlying Security	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(IIIsu. 4)		
ResMed Common Stock Options	\$146.34	12/08/2025		M (1)			4,991	11/11/2020 (3)	11/21/2026	ResMed Common Stock	4,991	\$0	54,903	D	

Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- 2. This transaction was executed in multiple trades at prices ranging from \$249.63 \$255.775. The price reported above reflects the weighted average sale price.

Represents date options first become exercisable. Options vest 1/3 per year.

/s/ Michael J. Farrell. Chairman and Cl

** Signature of Reporting Person

12/09/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.